Racial disparity in tumor microenvironment and distant recurrence in residual breast cancer after neoadjuvant chemotherapy

[1]  A. Bianchi,et al.  Assessment of MRI to estimate metastatic dissemination risk and prometastatic effects of chemotherapy , 2022, npj Breast Cancer.

[2]  Q. Sun,et al.  The Prognostic and Clinical Value of Tumor-Associated Macrophages in Patients With Breast Cancer: A Systematic Review and Meta-Analysis , 2022, Frontiers in Oncology.

[3]  T. Julian,et al.  Racial disparity in distant recurrence‐free survival in patients with localized breast cancer: A pooled analysis of National Surgical Adjuvant Breast and Bowel Project trials , 2022, Cancer.

[4]  T. Rohan,et al.  Combining TMEM Doorway Score and MenaCalc Score Improves the Prediction of Distant Recurrence Risk in HR+/HER2− Breast Cancer Patients , 2022, Cancers.

[5]  D. Esposito,et al.  Live tumor imaging shows macrophage induction and TMEM-mediated enrichment of cancer stem cells during metastatic dissemination , 2021, Nature Communications.

[6]  A. Jemal,et al.  Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries , 2021, CA: a cancer journal for clinicians.

[7]  J. Olson,et al.  Race, ethnicity and clinical outcomes in hormone receptor-positive, HER2-negative, node-negative breast cancer in the randomized TAILORx trial. , 2020, Journal of the National Cancer Institute.

[8]  T. Rohan,et al.  Validation of an Automated Quantitative Digital Pathology Approach for Scoring TMEM: A Prognostic Biomarker for Metastasis , 2020, Cancers.

[9]  Hung-Ming Wang,et al.  Baseline circulating stem-like cells predict survival in patients with metastatic breast Cancer , 2019, BMC Cancer.

[10]  Ahmedin Jemal,et al.  Breast cancer statistics, 2019 , 2019, CA: a cancer journal for clinicians.

[11]  J. Condeelis,et al.  Assessing Tumor Microenvironment of Metastasis Doorway-Mediated Vascular Permeability Associated with Cancer Cell Dissemination using Intravital Imaging and Fixed Tissue Analysis. , 2019, Journal of visualized experiments : JoVE.

[12]  J. Pollard,et al.  A Unidirectional Transition from Migratory to Perivascular Macrophage Is Required for Tumor Cell Intravasation , 2018, Cell reports.

[13]  Oguzhan Alagoz,et al.  Association of Screening and Treatment With Breast Cancer Mortality by Molecular Subtype in US Women, 2000-2012 , 2018, JAMA.

[14]  T. Rohan,et al.  Risk of Recurrence and Mortality in a Multi-Ethnic Breast Cancer Population , 2017, Journal of Racial and Ethnic Health Disparities.

[15]  R. Gray,et al.  A metastasis biomarker (MetaSite Breast™ Score) is associated with distant recurrence in hormone receptor-positive, HER2-negative early-stage breast cancer , 2017, npj Breast Cancer.

[16]  Tsonwin Hai,et al.  Stress-inducible gene Atf3 in the noncancer host cells contributes to chemotherapy-exacerbated breast cancer metastasis , 2017, Proceedings of the National Academy of Sciences.

[17]  H. Sebastian Seung,et al.  Trainable Weka Segmentation: a machine learning tool for microscopy pixel classification , 2017, Bioinform..

[18]  Thomas E Rohan,et al.  Neoadjuvant chemotherapy induces breast cancer metastasis through a TMEM-mediated mechanism , 2017, Science Translational Medicine.

[19]  J. Condeelis,et al.  Macrophage-dependent tumor cell transendothelial migration is mediated by Notch1/MenaINV-initiated invadopodium formation , 2016, Scientific Reports.

[20]  C. Blanpain,et al.  Cancer Stem Cells: Basic Concepts and Therapeutic Implications. , 2016, Annual review of pathology.

[21]  T. Rohan,et al.  Invasive breast carcinoma cells from patients exhibit MenaINV- and macrophage-dependent transendothelial migration , 2014, Science Signaling.

[22]  T. Rohan,et al.  Tumor microenvironment of metastasis and risk of distant metastasis of breast cancer. , 2014, Journal of the National Cancer Institute.

[23]  G. Hortobagyi,et al.  Which threshold for ER positivity? a retrospective study based on 9639 patients. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[24]  Johannes E. Schindelin,et al.  Fiji: an open-source platform for biological-image analysis , 2012, Nature Methods.

[25]  I. Ellis,et al.  A CD44−/CD24+ phenotype is a poor prognostic marker in early invasive breast cancer , 2012, Breast Cancer Research and Treatment.

[26]  E. Perez,et al.  Race and hormone receptor-positive breast cancer outcomes in a randomized chemotherapy trial. , 2012, Journal of the National Cancer Institute.

[27]  J. Condeelis,et al.  Mena invasive (MenaINV) and Mena11a isoforms play distinct roles in breast cancer cell cohesion and association with TMEM , 2011, Clinical & Experimental Metastasis.

[28]  G. Di,et al.  The prognostic role of cancer stem cells in breast cancer: a meta-analysis of published literatures , 2010, Breast Cancer Research and Treatment.

[29]  Dawn L Hershman,et al.  Racial disparities in cancer survival among randomized clinical trials patients of the Southwest Oncology Group. , 2009, Journal of the National Cancer Institute.

[30]  R. Stephens,et al.  Differences in the Tumor Microenvironment between African-American and European-American Breast Cancer Patients , 2009, PloS one.

[31]  J. A. van der Hage,et al.  Neoadjuvant chemotherapy for operable breast cancer , 2007, The British journal of surgery.

[32]  C. Perou,et al.  Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. , 2006, JAMA.

[33]  D. Nerenz,et al.  Comorbidity and survival disparities among black and white patients with breast cancer. , 2005, JAMA.

[34]  for the Statistics Subcommittee of the NCI—EORTC Worki Diagnostics.  REporting recommendations for tumor MARKer prognostic studies (REMARK) , 2005, Nature Clinical Practice Oncology.

[35]  Noam Brown,et al.  The role of tumour‐associated macrophages in tumour progression: implications for new anticancer therapies , 2002, The Journal of pathology.

[36]  P. Grambsch,et al.  Proportional hazards tests and diagnostics based on weighted residuals , 1994 .

[37]  David A. Schoenfeld,et al.  Partial residuals for the proportional hazards regression model , 1982 .

[38]  Anthony Rhodes,et al.  American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer (unabridged version). , 2010, Archives of pathology & laboratory medicine.